Skip to main content

Pharmaceutical News and Articles

Comprehensive and up-to-date drug news for both consumers and healthcare professionals.

Respect Summer's Scorching Heat, Experts Warn

SATURDAY, July 13, 2024 -- The human body is no match for extreme heat, and scorching temperatures seem to be the rule rather than the exception these...

CDC Reports Seven Cases of Illness After Possible Counterfeit Botox Injections

FRIDAY, July 12, 2024 -- Seven patients with illness identified after presumed cosmetic botulinum neurotoxin (BoNT) product injection are described in a case...

More Women Than Men Experience Nonphysical Violence in Health Care Workforce

FRIDAY, July 12, 2024 -- Women in the health care workforce are more likely to experience verbal abuse, sexual harassment, and bullying, while men are more...

CDC: Five Cases of Neonatal Enterovirus Infection Identified in San Diego

FRIDAY, July 12, 2024 -- Five cases of neonatal enterovirus infection have been reported in San Diego, highlighting the risks and need for timely...

Only One-Quarter of Patients Still Taking Semaglutide for Weight Loss Two Years Later

FRIDAY, July 12, 2024 -- Three of four patients stop taking semaglutide (Ozempic or Wegovy) two years after being prescribed the glucagon-like peptide-1...

Nightmares in Midlife May Point to Future Cognitive Decline, Dementia

FRIDAY, July 12, 2024 -- Distressing dreams in middle-aged and older adults may indicate a higher risk for future cognitive decline and all-cause dementia...

Thousands of Hospital Patients in Oregon May Have Been Exposed to Hepatitis, HIV

FRIDAY, July 12, 2024 -- After an anesthesiologist may have exposed thousands of people treated at several hospitals in Oregon to hepatitis and HIV, those...

Fake Botox Shots Land 13 Women in Hospital

FRIDAY, July 12, 2024 -- Seventeen women in nine states have fallen ill after getting fake Botox shots, with 13 of them landing in the hospital and one...

New Report Calls for More Research on Women's Health Issues

FRIDAY, July 12, 2024 -- A new report finds research is sorely lacking on how chronic illnesses affect women, and it urged government agencies to do more to...

Nearly 1 in 10 Pregnant Women Who Get COVID Develop Long COVID

FRIDAY, July 12, 2025 -- Almost 10% of women who get COVID during pregnancy develop long-lasting symptoms, and a new study suggests doctors may be overlooking...

FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...

FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss

South San Francisco, CA -- July 4, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug...

FDA Approves Kisunla (donanemab-azbt) for the Treatment of Early Symptomatic Alzheimer's Disease

INDIANAPOLIS, July 2, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly...

FDA Approves Ahzantive (aflibercept-mrbb), a Biosimilar to Eylea

Planegg-Martinsried, Germany July 1, 2024 – Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH...

FDA Approves Nypozi (filgrastim-txid), a Biosimilar to Neupogen

July 01, 2024 Tanvex BioPharma, Inc. (TWSE: 6541) announced that The U.S. Food and Drug Administration (FDA) had completed their review of our submission of...

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

STAMFORD, Conn., July 01, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on...

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

BASKING RIDGE, N.J. & RAHWAY, N.J., June 26, 2024 – The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the...

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

NORTH CHICAGO, Ill., June 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug...

Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

DUBLIN and CHICAGO, May 31, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on...

U.S. FDA Acknowledges Astellas' Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date

TOKYO, May 30, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug...

Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target are Prostate Cancer Patients Resistant to Hormone Therapy

SEOUL, South Korea, July 11, 2024. ADM Korea, a subsidiary of Hyundai Bioscience, announced on the 8th that the first clinical trial target population for its...

AskBio receives FDA Fast Track and MHRA Innovation Passport Designations for AB-1005 Investigational GDNF Gene Therapy for Parkinson’s Disease

Berlin, Germany, and Research Triangle Park, N.C., USA, July 11, 2024 – Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company...

Immunotherapy Approach Shows Potential in Some People with Metastatic Solid Tumors

July 11, 2024 -- Early findings from a small clinical trial provide evidence that a new cellular immunotherapy approach may be effective in treating metastatic...

Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron

NEW YORK--(BUSINESS WIRE) July 11, 2024 -- Pfizer Inc. (NYSE: PFE) today announced that based on results from the ongoing pharmacokinetic study (NCT06153758)...

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

SYDNEY, July 10, 2024. Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase II/III...

Browse by news type

Drugs.com Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Disclaimer

This library contains syndicated news articles. These articles have not been peer-reviewed by Drugs.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.